Regeneron Pharmaceuticals (REGN) Rating Lowered to Sell at ValuEngine
ValuEngine cut shares of Regeneron Pharmaceuticals (NASDAQ:REGN) from a hold rating to a sell rating in a research report sent to investors on Thursday.
A number of other analysts also recently issued reports on the company. Canaccord Genuity downgraded Regeneron Pharmaceuticals from a buy rating to a hold rating and reduced their price objective for the stock from $522.00 to $356.00 in a research note on Wednesday, February 21st. Zacks Investment Research raised Regeneron Pharmaceuticals from a sell rating to a strong-buy rating and set a $380.00 price objective on the stock in a research note on Friday, February 16th. BTIG Research reaffirmed a hold rating on shares of Regeneron Pharmaceuticals in a research note on Tuesday, February 13th. SunTrust Banks set a $430.00 price objective on Regeneron Pharmaceuticals and gave the stock a hold rating in a research note on Friday, February 9th. Finally, Morgan Stanley lifted their price objective on Regeneron Pharmaceuticals from $401.00 to $415.00 and gave the stock an equal weight rating in a research note on Friday, February 9th. Four analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have issued a buy rating and one has issued a strong buy rating to the stock. The company has an average rating of Hold and a consensus target price of $450.65.
Shares of Regeneron Pharmaceuticals (NASDAQ REGN) traded up $8.69 on Thursday, reaching $330.47. The company had a trading volume of 909,488 shares, compared to its average volume of 1,155,646. The company has a market cap of $35,590.30, a P/E ratio of 32.02, a PEG ratio of 1.04 and a beta of 1.54. Regeneron Pharmaceuticals has a 52 week low of $313.53 and a 52 week high of $543.55. The company has a debt-to-equity ratio of 0.11, a current ratio of 3.82 and a quick ratio of 3.18.
In related news, Director Joseph L. Goldstein sold 1,000 shares of the business’s stock in a transaction on Friday, February 9th. The stock was sold at an average price of $325.60, for a total transaction of $325,600.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 10.80% of the stock is owned by insiders.
A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Harding Loevner LP boosted its holdings in Regeneron Pharmaceuticals by 589.2% during the 3rd quarter. Harding Loevner LP now owns 3,663,548 shares of the biopharmaceutical company’s stock valued at $286,619,000 after acquiring an additional 3,131,966 shares during the period. Polen Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 1.2% during the 4th quarter. Polen Capital Management LLC now owns 1,389,545 shares of the biopharmaceutical company’s stock valued at $522,413,000 after acquiring an additional 15,931 shares during the period. American Century Companies Inc. boosted its holdings in Regeneron Pharmaceuticals by 2.3% during the 3rd quarter. American Century Companies Inc. now owns 917,554 shares of the biopharmaceutical company’s stock valued at $410,257,000 after acquiring an additional 20,218 shares during the period. Geode Capital Management LLC boosted its holdings in Regeneron Pharmaceuticals by 3.6% during the 4th quarter. Geode Capital Management LLC now owns 880,481 shares of the biopharmaceutical company’s stock valued at $330,385,000 after acquiring an additional 30,581 shares during the period. Finally, Franklin Resources Inc. boosted its holdings in Regeneron Pharmaceuticals by 4.5% during the 4th quarter. Franklin Resources Inc. now owns 819,796 shares of the biopharmaceutical company’s stock valued at $308,212,000 after acquiring an additional 35,123 shares during the period. Institutional investors own 64.67% of the company’s stock.
TRADEMARK VIOLATION WARNING: “Regeneron Pharmaceuticals (REGN) Rating Lowered to Sell at ValuEngine” was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another domain, it was copied illegally and reposted in violation of international copyright & trademark laws. The legal version of this piece can be accessed at https://www.watchlistnews.com/regeneron-pharmaceuticals-regn-rating-lowered-to-sell-at-valuengine/1907588.html.
Regeneron Pharmaceuticals Company Profile
Regeneron Pharmaceuticals, Inc is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis, asthma, atopic dermatitis, pain, cancer, and infectious diseases.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Regeneron Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regeneron Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.